扩张型心肌病发病机理及治疗进展

扩张型心肌病(DCM)以左心室或双心室扩张及收缩功能受损为特征,其发病机理主要与病毒感染后的自身免疫反应有关。80年代以后,遗传因素与DCM的关系逐渐受到重视。DCM的基本治疗是纠正心力衰竭,心律失常及预防血栓栓塞等并发症。针对免疫介导的心肌损伤的早期干预已成为DCM的主要治疗方法。在DCM早期应用地尔硫和β-受体阻滞剂治疗,可以阻止免疫介导的心肌损害,改善患者预后。

Progress of pathogenesis and treatment in dilated cardiomyopathy

Dilated cardiomyopathy (DCM) is characterized by the dilatation of left ventricle or biventrical accompanied by the impairment of the contractile force. The pathogenesis is concerned to have some connection with autoimmunity after infection for virus. Later of 1980's, it is more and more taken seriously that the relationship between genecics and DCM. The primary therapy for DCM is to cure complications including congestive heart failure, arrhythmia and thromboembolism. Intervention in early stage to aim directly at the myocardium impairment mediated by immunity is the main therapy for DCM. If treated with diltiazem and beta-adrenergic blocage in early stage of DCM, cardiac injury would be prevented and the prognosis improved.